ReviewJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2017
Recent Advances in Targeting ROS1 in Lung Cancer.
Review in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04137718 (Multicenter Observational Study for Clinicopathological Characteristics and Clinical Efficacy of Chinese Non-Small Cell Lung Cancer), which is not on this map. Cited by 134 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Observational Study for Clinicopathological Characteristics and Clinical Efficacy of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation
Who cites it
134 citing papers in PubMed, 1 synthesis or guideline pooled it, 255 citations in OpenAlex.
- Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis.Targeted oncology · 2020Pooled it
- A predictive model for fusion gene positivity in treatment-naive advanced non-small cell lung cancer.Translational lung cancer research · 2026Article
- Improvement of prognosis among patients with lung adenocarcinoma through precision therapy: analysis based on The Cancer Genome Atlas.Translational cancer research · 2026Article
- Molecular Docking and MD Modeling Techniques for the Development of Novel ROS1 Kinase Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Article
- Research progress of small molecule targeted drugs for non-small cell lung cancer.Frontiers in oncology · 2026Review
- Review
- Taletrectinib in ROS1+ non-small cell lung cancer: a cost-effectiveness analysis in the United States.Frontiers in pharmacology · 2026Article
- Increased Cardiovascular Risk With Lorlatinib in Patients With ALK-Mutated Lung Cancer: A Real-World Comparative Study.Journal of the American Heart Association · 2025Article
- Exploring mitochondrial ribosomal protein S12 as a novel target for non-small cell lung cancer.NPJ precision oncology · 2025Article
- Molecular Characteristics and Treatment Implications of TP53 Gain-of-Function Mutations in Non-Small Cell Lung Cancer.Cancer medicine · 2025Article
- Exploring the mutational spectrum of key kinase genes PIK3CA, BRAF, EGFR, ALK and ROS1 in oral squamous cell carcinoma.BMC cancer · 2025Article
- Resistance mutations and the blood-brain barrier: Key challenges in targeted treatment of brain metastatic non-small cell lung cancer.Acta pharmaceutica Sinica. B · 2025Review
- Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations.Molecular cancer therapeutics · 2025Article
- Recent advances in therapeutic strategies for non-small cell lung cancer.Journal of hematology & oncology · 2025Review
- Harnessing TAGAP to improve immunotherapy for lung squamous carcinoma treatment by targeting c-Rel in CD4+ T cells.Cancer immunology, immunotherapy : CII · 2025Article
- The expression and functional role of proline-rich 15 in non-small cell lung cancer.Cell death & disease · 2025Article
- Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China.Journal of comparative effectiveness research · 2025Review
- Identification of KRT16 and ANXA10 as cell cycle regulation genes for lung adenocarcinoma based on self-transcriptome sequencing of surgical samples and TCGA public data mining.Discover oncology · 2025Article
74 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
ROS1 is a validated therapeutic target in NSCLC. In a phase I study, the multitargeted MET proto-oncogene, receptor tyrosine kinase/anaplastic lymphoma kinase/ROS1 inhibitor crizotinib demonstrated remarkable efficacy in ROS1-rearranged NSCLCs and consequently gained approval by the United States Food and Drug Administration and by the European Medicines Agency in 2016. However, similar to other oncogene-driven lung cancers, ROS1-rearranged lung cancers treated with crizotinib eventually acquire resistance, leading to disease relapse. Novel ROS1 inhibitors and therapeutic strategies are therefore needed. Insights into the mechanisms of resistance to ROS1-directed tyrosine kinase inhibitors are now beginning to emerge and are helping to guide the development of new ROS1 inhibitors. This review discusses the biology and diagnosis of ROS1-rearranged NSCLC, and current and emerging treatment options for this disease. Future challenges in the field are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.